365 related articles for article (PubMed ID: 33511078)
1. PD-1 Blockade Aggravates Epstein-Barr Virus
Volk V; Theobald SJ; Danisch S; Khailaie S; Kalbarczyk M; Schneider A; Bialek-Waldmann J; Krönke N; Deng Y; Eiz-Vesper B; Dragon AC; von Kaisenberg C; Lienenklaus S; Bleich A; Keck J; Meyer-Hermann M; Klawonn F; Hammerschmidt W; Delecluse HJ; Münz C; Feuerhake F; Stripecke R
Front Oncol; 2020; 10():614876. PubMed ID: 33511078
[TBL] [Abstract][Full Text] [Related]
2. CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease.
Slabik C; Kalbarczyk M; Danisch S; Zeidler R; Klawonn F; Volk V; Krönke N; Feuerhake F; Ferreira de Figueiredo C; Blasczyk R; Olbrich H; Theobald SJ; Schneider A; Ganser A; von Kaisenberg C; Lienenklaus S; Bleich A; Hammerschmidt W; Stripecke R
Mol Ther Oncolytics; 2020 Sep; 18():504-524. PubMed ID: 32953984
[TBL] [Abstract][Full Text] [Related]
3. PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model.
Ma SD; Xu X; Jones R; Delecluse HJ; Zumwalde NA; Sharma A; Gumperz JE; Kenney SC
PLoS Pathog; 2016 May; 12(5):e1005642. PubMed ID: 27186886
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.
Sebelin-Wulf K; Nguyen TD; Oertel S; Papp-Vary M; Trappe RU; Schulzki A; Pezzutto A; Riess H; Subklewe M
Transpl Immunol; 2007 Apr; 17(3):203-10. PubMed ID: 17331848
[TBL] [Abstract][Full Text] [Related]
5. Successful management of EBV-PTLD in allogeneic bone marrow transplant recipient by virological-immunological monitoring of EBV infection, prompt diagnosis and early treatment.
Chiereghin A; Bertuzzi C; Piccirilli G; Gabrielli L; Squarzoni D; Turello G; Ferioli M; Sessa M; Bonifazi F; Zanoni L; Sabattini E; Lazzarotto T
Transpl Immunol; 2016 Feb; 34():60-4. PubMed ID: 26687013
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr Virus-Associated Post-transplant Lymphoproliferative Disease.
Ambinder RF
Recent Results Cancer Res; 2021; 217():197-207. PubMed ID: 33200367
[TBL] [Abstract][Full Text] [Related]
7. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
[TBL] [Abstract][Full Text] [Related]
8. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients.
Riddler SA; Breinig MC; McKnight JL
Blood; 1994 Aug; 84(3):972-84. PubMed ID: 8043879
[TBL] [Abstract][Full Text] [Related]
9. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
Chen DB; Wang Y; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
[TBL] [Abstract][Full Text] [Related]
10. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
11. Lymphocyte subset at time of Epstein-Barr viremia post-allogeneic hematopoietic stem cell transplantation in children may predict development of post-transplant lymphoproliferative disease: CD8:CD20 ratio as a sensitive predictor.
Althubaiti S; Ali S; Renzi S; Krueger J; Chiang KY; Schechter T; Punnett A; Ali M
Pediatr Transplant; 2019 Dec; 23(8):e13574. PubMed ID: 31496046
[TBL] [Abstract][Full Text] [Related]
12. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
Pfeffermann LM; Pfirrmann V; Huenecke S; Bremm M; Bonig H; Kvasnicka HM; Klingebiel T; Bader P; Rettinger E
Cytotherapy; 2018 Jun; 20(6):839-850. PubMed ID: 29754771
[TBL] [Abstract][Full Text] [Related]
14. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
[TBL] [Abstract][Full Text] [Related]
15. Spatiotemporally Skewed Activation of Programmed Cell Death Receptor 1-Positive T Cells after Epstein-Barr Virus Infection and Tumor Development in Long-Term Fully Humanized Mice.
Danisch S; Slabik C; Cornelius A; Albanese M; Tagawa T; Chen YA; Krönke N; Eiz-Vesper B; Lienenklaus S; Bleich A; Theobald SJ; Schneider A; Ganser A; von Kaisenberg C; Zeidler R; Hammerschmidt W; Feuerhake F; Stripecke R
Am J Pathol; 2019 Mar; 189(3):521-539. PubMed ID: 30593822
[TBL] [Abstract][Full Text] [Related]
16. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
Allen UD; Preiksaitis JK;
Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
[TBL] [Abstract][Full Text] [Related]
17. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice.
Caduff N; McHugh D; Murer A; Rämer P; Raykova A; Landtwing V; Rieble L; Keller CW; Prummer M; Hoffmann L; Lam JKP; Chiang AKS; Raulf F; Azzi T; Berger C; Rubic-Schneider T; Traggiai E; Lünemann JD; Kammüller M; Münz C
PLoS Pathog; 2020 Apr; 16(4):e1008477. PubMed ID: 32251475
[TBL] [Abstract][Full Text] [Related]
19. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
Mentzer SJ; Perrine SP; Faller DV
Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
[TBL] [Abstract][Full Text] [Related]
20. Non-uniform
Burns DM; Ryan GB; Harvey CM; Nagy E; Hughes S; Murray PG; Russell NH; Fox CP; Long HM
Front Immunol; 2019; 10():2489. PubMed ID: 31736946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
